Navigation Links
National Psoriasis Foundation awards $1.05 million in research grants
Date:7/16/2014

PORTLAND, Ore. (July 16, 2014)Thirteen scientists received a total of $1.05 million in funding from the National Psoriasis Foundation for projects that aim to identify new treatments and a cure for psoriasisan autoimmune disease that appears on the skin, affecting 7.5 million Americansand psoriatic arthritisan inflammatory arthritis that affects the joints and tendons, occurring in up to 30 percent of people with psoriasis.

Learn more about the NPF research grant program: http://www.psoriasis.org/research.

This year, three scientists each received a two-year, $200,000 National Psoriasis Foundation Translational Grant to "translate" their laboratory findings into improved treatments and methods for managing psoriatic disease.

The Translational Grant recipients and their projects are:

  • Kevin Cooper, M.D., of Case Western Reserve University in Cleveland received the Dr. Alan Menter Translational Grant, named in recognition of one of the world's leading psoriatic disease experts. Cooper will determine whether systemic psoriasis treatments can reduce the risk for cardiovascular disease.

  • Lorena Riol Blanco, Ph.D., of Harvard Medical School will study how pain fibers drive the production of interleukin-23 (IL-23), a protein linked to inflammation, to find new therapies for psoriasis inflammation.

  • Michael Rosenblum, M.D., Ph.D., of the University of California, San Francisco, will examine the role of a special class of regulatory T-cells involved in suppressing inflammation, in people with psoriasis. He aims to discover why these cells function abnormally in psoriasis to develop treatments to repair them and treat psoriasis.

    Additionally, 10 researchers each received a one-year, $75,000 Discovery Grant for early-stage psoriatic disease research.

    The Discovery Grant recipients and their projects are:

  • Rachael Clark, M.D., Ph.D., of the Brigham & Women's Hospital at Harvard University, will study T-cells, which are involved in inflammation, that remain in healed psoriasis lesions and compare them to T-cells in the same patient's skin before treatment. Clark hopes to determine if these T-cells are the root cause of psoriasis.

  • Dan Illkovitch, M.D., Ph.D., of University of Pittsburgh Medical Center, received the Ostrow Graff Family Discovery Grant to study an immune cell called myeloid‐derived suppressor cells, which have not been extensively studied in psoriasis. He will examine the role that these cells play in psoriasis, and examine whether they are affected by psoriasis treatment.

  • Jaehwan Kim, M.D, Ph.D., of The Rockefeller University will develop a blood test that can predict a person's treatment response to a biologic drug for psoriasis.

  • Averil Ma, M.D., of University of California, San Francisco, will examine how reducing the expression of the A20 gene, previously implicated in the genetics of psoriasis, may increase psoriasis risk. Studying how A20 functions in psoriasis could lead to treatments that are better tailored for people with variations of A20.

  • Pranab Mukherjee, Ph.D., of Case Western Reserve University, received the Lozick Discovery Research Grant to study the role of the skin microbiome and mycobiome, or microorganisms and fungi on the skin, in the development of psoriasis.

  • Haley Naik, M.D., of the National Cancer Institute dermatology branch, will study neutrophils, or cells thought to be a unique link between psoriasis, heart disease and diabetes. Naik hopes to uncover more about the role of these cells in psoriasis and their relation to psoriasis severity and related health risks.

  • Brian Poligone, M.D., Ph.D., of University of Rochester School of Medicine, received the Galderma Discovery Grant to study NF-kappa Ba transcription factor, or protein that binds to DNA, that regulates inflammation in the body. He will investigate the role of NF-kappa B in triggering psoriasis, and explore ways to control its activity.

  • Eva Reali, Ph.D., of Istituto Ortopedico Galeazzi in Milan, received the A. Marilyn Sime Discovery Grant to study the connection between pro-inflammatory T-cells in psoriasis skin and joint inflammation of psoriatic arthritis. Reali will define distinctive characteristics of these cells to hopefully create a biomarker, or biological sign, for the development of psoriatic arthritis in psoriasis patients.

  • Jubin Ryu, M.D., Ph.D., of University of California, San Francisco, aims to develop a new method for delivering biologic drugs, currently administered through injection or infusion, via a skin patch to allow for localized, less invasive treatment. 1
  • Eric Sundberg, Ph.D., of University of Maryland School of Medicine, hopes to create novel molecules that suppress interleukin-36 (IL-36), a protein that drives inflammation. These molecules could lead to the development of a new, targeted psoriasis treatment.


    '/>"/>

  • Contact: Noe Baker
    nbaker@psoriasis.org
    503-546-8416
    National Psoriasis Foundation
    Source:Eurekalert

    Related medicine news :

    1. Internationally renowned surgeon Angelita Habr-Gama, MD, PhD, named 2014 ASTRO Honorary Member
    2. National Patient Safety Foundation President Tejal Gandhi to Address Senate on the Need to Improve Patient Safety
    3. 5K To Marathon Training Website, Rundreamachieve, Adds The R.D.A. Max International Team To List Of Services
    4. Acoustiblok Wins Challenge on National Television Series
    5. Sport Court Provides All Sports Surfaces for New International Olympic Committee Training Center in Haiti
    6. First National Technology Solutions Now Offering xTremIO Capability
    7. Praeclarus Press Announces The Release of Three New Breastfeeding Support Books For International Lactation Consultant Association's Annual Conference, July 22-25, 2014
    8. National Association of Professional Women Announces Pamela Erlandson, Owner, Erlandson Surgical & Medical Legal Consulting Svcs, as a 2014 Professional Woman of the Year
    9. National Association of Professional Women Announces Elizabeth (Betsy) L.M. Miller, Founder, Child Care Health & Safety, LLC, as a 2014 Professional Woman of the Year
    10. National Association of Professional Women Announces Dr. Karen Riedel, Director of Speech Language Pathology, NYU Medical Center, as a 2014 Professional Woman of the Year
    11. Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
    (Date:3/24/2017)... ... March 24, 2017 , ... Gastro ... their partnership to prep patients for colonoscopy at the HyGIeaCare® Center that is ... Ave., Miami, FL. , The HyGIeaCare® Prep, cleared by the U.S. ...
    (Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation ... and college Bible teacher residing in North Carolina with his wife, Anna Marie. He ... them with six grandchildren. David is also the author of “Shadow and Substance.” , ...
    (Date:3/23/2017)... ... 2017 , ... The physicians of KSF Orthopaedic Center PA are proud to ... location is located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 ... provide patients living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) ...
    (Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
    Breaking Medicine News(10 mins):
    (Date:3/24/2017)... Research and Markets has announced the ... Strategies" report to their offering. ... Pain Management in the ... their physical pain, emphasizing consumer survey analysis, including trends over ... adults who have selected illnesses/conditions strongly associated with physical pain ...
    (Date:3/24/2017)... 24, 2017 ShangPharma, a leading ... cost-effective drug development and discovery services, technology, ... industry, announced today the intent for a ... be consolidating the Contract Research Organizations (CRO) ... ChemPartner. These entities include ChemPartner Shanghai, ChemPartner ...
    (Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
    Breaking Medicine Technology: